Question 1

What is Insulet's P/S ratio?

Accepted Answer

Insulet (PODD) P/S ratio is 3.7× as of June 5, 2026. The ratio is calculated by dividing market capitalisation by trailing twelve-month revenue, using USD-normalised financials (IAS 21 exchange-rate translation for non-USD reporters).

Question 2

How is the P/S ratio calculated?

Accepted Answer

P/S = Market Capitalisation ÷ Trailing Twelve-Month (TTM) Revenue, or equivalently Share Price ÷ TTM Revenue Per Share. All inputs are sourced from audited GAAP/IFRS filings and translated to USD using period-end exchange rates so the multiple is comparable across companies and currencies.

Question 3

What is the P/S ratio?

Accepted Answer

The price-to-sales (P/S) ratio compares a company's market capitalisation to its trailing twelve-month (TTM) revenue. It is calculated as market cap ÷ TTM revenue (equivalent to share price ÷ TTM revenue per share). Because the denominator (revenue) cannot be negative, P/S is widely used to value unprofitable or pre-profit companies and to make cross-sector comparisons.

Question 4

What is a good P/S ratio for Insulet?

Accepted Answer

A "good" P/S depends heavily on profit margin and growth: software and other high-margin businesses often command 5–15× sales, while low-margin retailers and commodity producers typically trade below 1×. Compare against sector peers rather than absolute thresholds. For Insulet specifically, the relevant sector benchmark is the current sector median of 3.5×.

Question 5

Is Insulet's P/S ratio high or low?

Accepted Answer

Insulet's P/S ratio of 3.7× is below its own 5-year average of 11.4× and above the sector median of 3.5×. That places the current reading at the 1th percentile of its 10-year history. A higher multiple usually reflects stronger expected growth, lower perceived risk, or higher returns on capital; a lower multiple reflects the opposite.

Question 6

What is Insulet's historical P/S ratio range?

Accepted Answer

In the available daily series, Insulet (PODD) P/S ratio has ranged from a low of 1.5× in 2007 to a high of 52.5× in 2007. The 5-year average is 11.4× and the 5-year median is 9.1×.

Question 7

What was Insulet's P/S ratio in 2025?

Accepted Answer

Insulet (PODD) P/S ratio at the end of 2025 was 7.4×. Annual values reflect the multiple on the last trading day of each calendar year, using the trailing twelve-month revenue figure available at that date.

Question 8

Why does Insulet's P/S ratio change over time?

Accepted Answer

Valuation multiples move with two inputs: the numerator (market capitalisation, which tracks the share price) and the denominator (revenue). Share-price changes — driven by interest rates, earnings expectations, risk appetite, and broader market sentiment — typically dominate short-term moves, while changes in the underlying fundamental drive the longer-term trend. As a result, the ratio can rise during stock-price rallies even if the business itself has not become more valuable, and fall during sell-offs even when fundamentals are improving.


2025	$20.00B	$2.71B	7.4×	-1.5×	Dec 31, 2025
2024	$18.32B	$2.07B	8.8×	-0.1×	Dec 31, 2024
2023	$15.16B	$1.70B	8.9×	-6.7×	Dec 31, 2023
2022	$20.45B	$1.31B	15.7×	-1.1×	Dec 31, 2022
2021	$18.38B	$1.10B	16.7×	-1.9×	Dec 31, 2021
2020	$16.86B	$904.40M	18.6×	+4.2×	Dec 31, 2020
2019	$10.68B	$738.21M	14.5×	+6.2×	Dec 31, 2019
2018	$4.69B	$563.82M	8.3×	-0.2×	Dec 31, 2018
2017	$3.95B	$463.77M	8.5×	+2.8×	Dec 31, 2017
2016	$2.10B	$366.99M	5.7×	-0.9×	Dec 31, 2016
2015	$2.15B	$324.23M	6.6×	-2.3×	Dec 31, 2015
2014	$2.59B	$288.72M	9.0×	+0.8×	Dec 31, 2014
2013	$2.03B	$247.08M	8.2×	+3.4×	Dec 31, 2013
2012	$1.02B	$211.37M	4.8×	-1.0×	Dec 31, 2012
2011	$893.01M	$152.25M	5.9×	-1.4×	Dec 31, 2011
2010	$706.54M	$96.97M	7.3×	-0.9×	Dec 31, 2010
2009	$541.04M	$66.03M	8.2×	+2.2×	Dec 31, 2009
2008	$214.33M	$36.06M	5.9×	-41.9×	Dec 31, 2008
2007	$639.22M	$13.37M	47.8×	+43.8×	Dec 31, 2007
2006	$14.64M	$3.66M	4.0×	—	Dec 31, 2006
2005	$12.69M	$0.00	—	—	Dec 31, 2005


Zimmer Biomet Holdings (ZBH)	2.1×
AptarGroup (ATR)	2.1×
Becton, Dickinson and (BDX)	2.1×
Charles River (CRL)	1.9×
Quest Diagnostics (DGX)	1.9×
IQVIA (IQV)	1.7×
GE HealthCare (GEHC)	1.6×
Labcorp Holdings (LH)	1.6×
HCA Healthcare (HCA)	1.4×
Solventum (SOLV)	1.4×
Viatris (VTRS)	1.1×
Baxter International (BAX)	0.8×
DaVita (DVA)	0.7×
Henry Schein (HSIC)	0.6×
Universal Health Services (UHS)	0.6×
UnitedHealth Group (UNH)	0.5×
Elevance Health (ELV)	0.3×
McKesson (MCK)	0.3×
Cigna (CI)	0.3×
CVS Health (CVS)	0.2×
Cardinal Health (CAH)	0.2×
Cencora (COR)	0.2×
Humana (HUM)	0.2×
Molina Healthcare (MOH)	0.2×
Centene (CNC)	0.1×

P/S Ratio for Insulet (PODD)

P/S Ratio daily chart for Insulet (PODD)

Historical P/S Ratio for Insulet (PODD) from 2005 to 2025

About P/S Ratio at Insulet (PODD)

Insulet P/S Ratio by Year

Insulet P/S Ratio 2025: 7.4×

Insulet P/S Ratio 2024: 8.8×

Insulet P/S Ratio 2023: 8.9×

Insulet P/S Ratio 2022: 15.7×

Insulet P/S Ratio 2021: 16.7×

Sector peers by P/S Ratio — chart

Sector peers by P/S Ratio — table

Frequently asked questions

Insulet (PODD) Key Financials

P/S Ratio daily chart for Insulet (PODD)

Historical P/S Ratio for Insulet (PODD) from 2005 to 2025

About P/S Ratio at Insulet (PODD)

Insulet P/S Ratio by Year

Insulet P/S Ratio 2025: 7.4×

Insulet P/S Ratio 2024: 8.8×

Insulet P/S Ratio 2023: 8.9×

Insulet P/S Ratio 2022: 15.7×

Insulet P/S Ratio 2021: 16.7×

Sector peers by P/S Ratio — chart

Sector peers by P/S Ratio — table

Frequently asked questions

+What is Insulet's P/S ratio?

+How is the P/S ratio calculated?

+What is the P/S ratio?

+What is a good P/S ratio for Insulet?

+Is Insulet's P/S ratio high or low?

+What is Insulet's historical P/S ratio range?

+What was Insulet's P/S ratio in 2025?

+Why does Insulet's P/S ratio change over time?

Insulet (PODD) Key Financials